32
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Nano drug (AgNPs capped with hydroxychloroquine): Synthesis, characterization, anti-covid-19 and healing the wound infected with S. aureus

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Almost existing anti-viral drugs are only organic molecules that are able to circumvent the system the virus works with, which leaves it facing the immune system of our bodies and then kills it. Unfortunately, this type of pharmacological fight did not succeed in a way to overcome this virus, so it became necessary to think outside the box, to find a drug that would kill the virus or alter its protein structure. This research aims to prepare silver nanoparticle (AgNPs) by the green method depending on the reaction of the silver nitrate (safe for humans) with the phoenix dactylifera extract (safe for humans) and then coated with the hydroxychloroquine (HQ, known antiviral drug). This substance will fight the virus with different mechanisms (i) silver will carry the drug to cells easily, and then (ii) nano silver will perform a physical inhibition of the virus and thus reduce its susceptibility to binding to host cells. In addition, (iii) silver nanoparticle is much smaller than the size of the virus which qualifies it to cross into the virus and change the structure of RNA. Furthermore, (iv) it is possible for silver to interact with the amino and carboxylic ends in the virus proteins. The results of TCID50 shows that the prepared nano drug is able to reduce the viability of covid-19 to about 22% using 400 mg/ml of AgNPs/HQ. The resulted nanodrug was also used for healing the wound infected with S. aureus and the histological results revealed that all of the disease symptoms improved, with the epidermal layer multiplying quickly and the infected wounds healing quickly.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          A Novel Coronavirus from Patients with Pneumonia in China, 2019

          Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

            Electronic supplementary material Supporting Information Supporting Information
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.

              A novel coronavirus has been identified as the causative agent of severe acute respiratory syndrome (SARS). The viral main proteinase (Mpro, also called 3CLpro), which controls the activities of the coronavirus replication complex, is an attractive target for therapy. We determined crystal structures for human coronavirus (strain 229E) Mpro and for an inhibitor complex of porcine coronavirus [transmissible gastroenteritis virus (TGEV)] Mpro, and we constructed a homology model for SARS coronavirus (SARS-CoV) Mpro. The structures reveal a remarkable degree of conservation of the substrate-binding sites, which is further supported by recombinant SARS-CoV Mpro-mediated cleavage of a TGEV Mpro substrate. Molecular modeling suggests that available rhinovirus 3Cpro inhibitors may be modified to make them useful for treating SARS.
                Bookmark

                Author and article information

                Journal
                Mater Chem Phys
                Mater Chem Phys
                Materials Chemistry and Physics
                Elsevier B.V.
                0254-0584
                0254-0584
                12 May 2022
                1 August 2022
                12 May 2022
                : 287
                : 126249
                Affiliations
                [a ]Department of Tikrit Education, Directorate of Salah El-din, Ministry of Education, Tikrit, Iraq
                [b ]Department of Nursing, Al-Hadi University College, Baghdad, Iraq
                [c ]Department of Dentistry, Al-Hadi University College, Baghdad, Iraq
                [d ]Department of Epidemiology, Faculty of Public Health & Tropical Medivine, Jazan University, Jazan, Saudi Arabia
                Author notes
                []Corresponding author.
                Article
                S0254-0584(22)00555-7 126249
                10.1016/j.matchemphys.2022.126249
                9096690
                1a91532c-1038-4292-a87f-25a1756f22fe
                © 2022 Elsevier B.V. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 23 March 2020
                : 22 April 2022
                : 9 May 2022
                Categories
                Article

                covid-19,agnps,green method,hydroxychloroquine
                covid-19, agnps, green method, hydroxychloroquine

                Comments

                Comment on this article